Download

CAMBRIDGE, Mass.--(BUSINESS WIRE)--ReadCoor, Inc., a company reinventing omics and pathology with its
panomic spatial sequencing platform, and WAVE Life Sciences Ltd.
(NASDAQ: WVE), a genetic medicines company focused on developing
targeted therapies for patients impacted by rare diseases, today
announced the initiation of a research collaboration to develop a
registry of brain cell network maps and advance WAVE’s nucleic acid
chemistry for targeted delivery to the brain.

Over the next two years, ReadCoor and WAVE have agreed to develop a cell
map of the mouse brain and to leverage it to characterize stereopure
nucleic acid candidates in specific regions, cell types, and subcellular
compartments of the brain. This agreement marks the first major industry
collaboration for ReadCoor and increases the number of platform
collaborations aimed at unlocking next generation targets for WAVE.

ReadCoor’s proprietary FISSEQ (Florescent In-Situ Sequencing) platform
is designed to provide critical spatial data by combining next
generation sequencing and three-dimensional imaging. This unique in-situ
sequencing technique is expected to provide meaningful insight of
disease state, treatment effects, and outcomes at the molecular level.
WAVE’s drug development platform is designed to enable the development
of stereopure nucleic acid therapeutics, with optimized efficacy,
stability, safety, and specificity. By leveraging ReadCoor’s technology,
WAVE expects to increase its ability to identify transcriptome changes
at the regional, cellular, and subcellular levels within the central
nervous system and to expand its existing discovery capabilities for
next generation candidate development.

Shawn Marcell, CEO of ReadCoor said, “WAVE’s unique ability to
rationally design nucleic acid therapeutic candidates and ReadCoor’s
distinctive ability to deliver in-situ spatial data in cells are highly
complementary. We are excited to expand the use of FISSEQ in our first
industry collaboration with WAVE.”

“At WAVE, one of our founding principles is that you cannot truly
optimize nucleic acid therapeutics using mixtures of molecules. We
believe the same is true when targeting biology using mixtures of cell
types,” said Paul B. Bolno, M.D., President & CEO of WAVE. “We believe
the ReadCoor platform will help enable significantly improved resolution
of various neurons, astrocytes and glial cells, thereby assisting WAVE
to efficiently select the optimal therapeutic modality for WAVE’s next
generation of pipeline candidates.”

About ReadCoor, Inc.

ReadCoor is leading the next generation of omics by delivering the first
panomic spatial sequencing platform to the global audience of
researchers, clinicians, pharma and diagnostics companies, and
ultimately patients. It is accomplishing this with Fluorescent In-Situ
Sequencing (FISSEQ), a fundamental new technology, which simultaneously
integrates high throughput sequencing, and three-dimensional
morphometric analysis. This uniquely powerful platform is expected to
revolutionize the next phase in understanding the panomic landscape and
may introduce vast new opportunities for important and meaningful
clinical insight.

About WAVE Life Sciences

WAVE Life Sciences is a genetic medicines company with an innovative and
proprietary synthetic chemistry drug development platform that WAVE is
using to design, develop and commercialize a broad pipeline of
first-in-class or best-in-class nucleic acid therapeutic candidates for
genetically defined diseases. WAVE is initially developing
oligonucleotides that target genetic defects to either reduce the
expression of disease-promoting proteins or transform the production of
dysfunctional mutant proteins into the production of functional proteins.

Forward Looking Information

This press release contains forward-looking statements, including
statements relating to the distinguishing features of WAVE’s drug
development platform and of ReadCoor’s sequencing technology, and the
potential benefits that each party anticipates deriving from the
collaboration. These statements may be identified by words such as
“believe,” “expect,” “may,” “plan,” “potential,” “will” and similar
expressions, and are based on current beliefs and expectations. These
statements involve risks and uncertainties that could cause actual
results to differ materially from those reflected in such statements,
including, as it relates to WAVE, risks and uncertainties associated
with drug development, the regulatory approval process and
commercialization, the development and acceptance of therapies with new
technologies, as well as other risks and uncertainties that are
described in the Risk Factors section of WAVE’s most recent annual or
quarterly report filed with the U.S. Securities and Exchange Commission.
Any forward-looking statements speak only as of the date of this press
release and the parties assume no obligation to update any
forward-looking statements, whether as a result of new information,
future events or otherwise.